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Background. Since the FEV1/FVC ratio declines with age, using the ﬁxed ratio of 0.70 leads to overdiagnosis of COPD in older
populations and underdiagnosis among young adults. Objective. To evaluate whether discordant obstructive cases (FEV1/FVC <
0.70 but ≥LLN) are a healthy population or have clinical features that would place them at increased risk. Methods.W eu s e d
post-bronchodilator spirometry data from the population-based Austrian Burden of Obstructive Lung Disease (BOLD) study.
Those with post-bronchodilator FEV1/FVC ratio <LLN and <0.70 were deﬁned as concordant obstructive cases.P a r t i c i p a n t sw i t h
post-bronchodilator FEV1/FVC ratio ≥LLN but <0.70 were deﬁned as discordant obstructive cases. Results. Discordant obstructive
cases were more likely to be older, male and never-smokers. Additionally they had less respiratory symptoms and less severe
impairment of FEV1. However, discordant obstructive cases reported signiﬁcantly more often a diagnosis of heart disease than
subjects with normal lung function (27.2% vs 7.3%, P = .015). Conclusion. The clinical proﬁle of discordant obstructive cases
includes potentially important comorbid disease.
1.Introduction
Lung function measurements are recommended as essential
for diagnosing COPD and helpful for grading its severity
[1].
According to current GOLD guidelines [2], chronic
obstructive pulmonary disease is deﬁned as airﬂow limita-
tion with a postbronchodilator FEV1/FVC ratio below 70%.
On the one hand, these criteria have simpliﬁed the
diagnosis of COPD and have helped to improve the aware-
ness of this disease. But on the other hand, the use of a
ﬁxed threshold to deﬁne airways obstruction is associated
with some extent of misclassiﬁcation. Since the FEV1/FVC
ratio declines with age, there is a risk of overdiagnosis of
COPD among healthy elderly people [3]. Because of this
misclassiﬁcation problem, the American Thoracic Society/
European Respiratory Society guidelines [4]c o n t i n u et o
oﬃcially recommend an interpretative algorithm that uses
the 5th percentile lower limit of normal (LLN), which is age-
speciﬁc and declines with age, to deﬁne pulmonary function
abnormalities.
For this study, we analyzed postbronchodilator spirom-
etry data of an Austrian population-based survey in adults
aged 40 years and over. We compared the ﬁxed ratio with
the lower limit of normal as a diagnostic criterion for
nonreversible airways obstruction. We tested the hypothesis
that discordant obstructive cases (FEV1/FVC < 0.70 and
≥LLN) are a healthy population (i.e., they are elderly,
asymptomatic subjects without the presence of known risk
factors for chronic airways obstruction) or whether these in-
between cases might represent subjects at risk who should be
followed carefully.2 Pulmonary Medicine
2.Methods
2.1. Study Population. The study population consisted of
participants of the Austrian Burden of Obstructive Lung
Disease (BOLD) study [5]. In this study, a gender-stratiﬁed
random sample of the inhabitants of Salzburg County, aged
40 years and over, was surveyed. Of the 2,200 individuals
(1,100 men and 1,100 women) whom we attempted to
contact, 1,258 (60%) completed the full protocol and had
spirometry ﬁndings thatmet ATSqualitycontrolcriteria(see
below). These individuals constitute the primary sample for
this analysis. The study was approved by the local Ethics
Committee of Salzburg County, and all participants gave
written informed consent.
2.2. Study Measures. Spirometry was done according to
American Thoracic Society (ATS) criteria [6]b yt r a i n e da n d
certiﬁed technicians using the NDD Easy One spirometer
with participants in a seated position. Separate measure-
ments were made before and at least 15 minutes after
two puﬀs of salbutamol (200μg) metered dose inhaler,
administered using a Volumatic spacer. Spirometry data
were sent electronically to the Pulmonary Function Quality
Control Centre in Salt Lake City, Utah, USA, where each
spirogram was reviewed and graded using ATS guidelines
[6].
Only spirograms that met ATS acceptability and repro-
ducibility criteria were included; at least three trials, two
acceptable(freefromartefact,suddenstops,andbackextrap-
olated volumes greater than 5.0% of FVC) and reproducible
(diﬀerence between largest and second largest values is less
than 200mL) tests for both the forced expiratory volume
in one-second (FEV1) and the forced vital capacity (FVC).
Study technicians were continuously monitored. When a
technician’squalityscoredroppedbelowapresetlevel,he/she
had to stop testing and be retrained and recertiﬁed.
2.3.Questionnaire Data. The BOLDquestionnaires included
information on respiratory symptoms, risk factors for
COPD, comorbidities, and respiratory diagnoses, and were
administered by a trained and certiﬁed staﬀ.
2.4. Deﬁnitions. Nonreversible “airways obstruction”w a s
deﬁnedeitherasapostbronchodilatorFEV1/FVCratiobelow
thelowerlimitofnormal(LNN)oranFEV1/FVCratiobelow
0.70 (according to GOLD criteria).
The NHANES III reference equations [7]w e r eu s e dt o
calculate predicted values and LLNs for FEV1, FVC, and
FEV1/FVC. The Lowerlimit of normal (LLN)is based on the
lower ﬁfth percentile of the index.
I nthepr es enc eofanabnormalFE V1/FV Cratio ,“severity
of airway obstruction” was graded as follows, possible normal
variant (FEV1 > 100% predicted), mild (FEV1 70–100%
predicted), moderate (FEV1 50–70% predicted), and severe
(FEV1 < 50% predicted).
Participants whose postbronchodilator FEV1/FVC ratio
was below both the LLN and the ﬁxed ratio of 0.70 were
deﬁned as “concordant obstructive cases”.
Table 1: Population characteristics and postbronchodilator lung
function data (n = 1258).
Male Female
Subjects, n (%) 685 (54.5%) 573 (45.5%)
Age distribution yrs, n (%)
40–50 206 (30.1%) 183 (31.9%)
51–60 202 (29.5%) 175 (30.5%)
61–70 169 (24.7%) 136 (23.7%)
71–80 83 (12.1%) 57 (10.0%)
81+ 25 (3.6%) 22 (3.9%)
Body mass index [kg/(m2)],
mean (SD) 26.7 (0.14) 26.1 (0.20)
FVC (L), mean (%pred.) 4.5 (97.5%) 3.4 (100.6%)
FEV1 (L), mean (%pred.) 3.4 (95.0%) 2.5 (95.9%)
FEV1/FVC%, mean (%pred.) 74.1 (97.6%) 74.5 (95.5%)
Participants who had a postbronchodilator FEV1/FVC
ratio above the LLN but below the ﬁxed ratio of 0.70 were
deﬁned as “discordant obstructive cases”.
“Restrictive lung function” was deﬁned as postbron-
chodilator FVC < 80% predicted and a FEV1/FVC > 70%.
“Doctor-diagnosed COPD” was deﬁned as self-reported
physician’s diagnosis of chronic bronchitis, emphysema, or
COPD.
“Ever smoking” (current or former smoking) was deﬁned
as smoking more than 20 packs of cigarettes in a lifetime
or more than 1 cigarette/day for a year. “Never smoking”
w a sd e ﬁ n e da ss m o k i n gl e s st h a n2 0p a c k so fc i g a r e t t e si na
lifetime.
Additional measures evaluated included self-report of
respiratory symptoms for “cough”( Do you usually cough
when you don’t have a cold?), “phlegm”( Do you usually bring
up phlegm from your chest, or do you usually have phlegm in
your chest that is diﬃcult to bring up when you don’t have a
cold?), and “dyspnea”( Are you troubled by shortness of breath
when hurrying on the level or walking up a slight hill?); and
“self-reported physician diagnosis” of asthma, tuberculosis,
heart disease, hypertension, diabetes, and stroke.
2.5. Statistical Analysis. Sensitivity and speciﬁcity of
FEV1/FVC < LLN for diagnosing airway obstruction deﬁned
by FEV1/FVC < 0.70 were calculated using 2 × 2t a b l e s .
Statistical signiﬁcance of diﬀerences was evaluated using the
chi-square test and the nonparametric Wilcoxon test. All
statistical analyses were done with SAS 8.2 (SAS Institute,
Inc., Cary, NC).
3.Results
Of the 1349 participants with postbronchodilator spirom-
etry, 1258 (93%) met the quality control criteria and
were included in this analysis. Population characteristics
and postbronchodilator lung function data of the study
population (n = 1258) are shown in Table 1.Pulmonary Medicine 3
Table 2: Airways obstruction deﬁned by postbronchodilator FEV1/
FVC < 0.70 and FEV1/FVC < LLN.
FEV1/FVC < 0.70
(n = 304)
FEV1/FVC ≥ 0.70
(n = 954)
FEV1/FVC < LLN
(n = 199) 192 (63.2%) 7 (0.7%)
FEV1/FVC ≥ LLN
(n = 1059) 112 (36.8%) 947 (99.3%)
Applying the current GOLD criteria (FEV1/FVC < 0.70)
to postbronchodilator spirometry, the prevalence of COPD
GOLD stage I or higher in our population-based sample
of adults aged 40 years and over was 24.2%. In contrast to
this, utilization of the lower limit of normal as a threshold
for the FEV1/FVC ratio (FEV1/FVC < LLN) demonstrated a
prevalence of 15.3%. Prevalence of doctor-diagnosed COPD
(reported physicians diagnosis of COPD, emphysema, or
chronic bronchitis) was 5.6%.
Figure 1 shows the declining FEV1/FVC ratio by age in
the study group without airways obstruction (n = 1059,
FEV1/FVC > LLN). The prevalence of COPD by diagnostic
deﬁnition and age group is illustrated in Figure 2.S e n s i t i v i t y
and speciﬁcity ofthewidely used ﬁxed ratio (0.70)compared
to the lower limit of normal are shown in Table 2.
Concordant obstructive cases (FEV1/FVC < 0.70 &
<L L N )s h o w e dat r e n dt o w a r d sm o r es e v e r ea i r w a y so b s t r u c -
tion than discordant obstructive cases (FEV1/FVC < 0.70 &
≥LLN), see Table 3. 89.3% of discordant obstructive cases
had a FEV1greaterthan 70%ofitspredictedvalue,and none
of the discordant obstructive cases had a FEV1 less than 50%
of its predicted value.
Overall, 6.4% (n = 81) of the study population were
discordant obstructive cases (FEV1/FVC < 0.70 & ≥LLN)
with mild to moderate obstructive impairment (FEV1 100–
50% predicted). Concordant obstructive and discordant
obstructivecaseswith mild tomoderateimpairment of FEV1
diﬀered signiﬁcantly in terms of age, gender, and reported
coughandphlegm(seeTable 4).However,whenadjustments
for age were made, they were very similar in terms of
comorbiddisease, smoking status, andreported dyspnea (see
Table 4).
The clinical proﬁle of subjects with discordant obstruc-
tive ﬁndings was similar to the proﬁle of subjects with
restrictive lung function (see Table 4). In addition to this,
subjects with discordant obstructive ﬁndings (FEV1/FVC <
0.70 & ≥LLN) reported signiﬁcantly more often a diagnosis
of heart disease than subjects with “normal” lung function
(FEV1/FVC>0.70 & FVC ≥ 80% pred.), see Table 4.
4.Discussion
This population-based study contributes to the charac-
terization of discordant obstructive cases (=subjects with
“normal” ﬁndings using the LLN but abnormal ﬁndings
usingtheﬁxedcutoﬀof70%asathresholdfortheFEV1/FVC
ratio). The data suggest that subjects who are in between
the two deﬁnitions of airways obstruction may not have
100
Age(years)
40 50 60
60
70
70
80
80
90
90
100
F
E
V
1
/
F
V
C
(
%
)
Figure 1: Study subjects with FEV1/FVC > LLN (n = 1059): rela-
tionship between FEV1/FVC% and age. Lines represent regression
ofFEV1/FVCratiobyage(solidline)with95%conﬁdencelimitsfor
mean predicted values (dotted lines). The horizontal line indicates
the 70% level of the FEV1/FVC ratio.
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Figure 2:Prevalence ofnonreversibleairwaysobstruction with age,
using diﬀerent deﬁnitions (per 1000 population). “Fixed ratio”:
postbronchodilator FEV1/FVC < 0.70, “LLN”: postbronchodilator
FEV1/FVC < LLN, “doctor diagnosis”:prior physiciansdiagnosisof
COPD.
clinically signiﬁcant airways obstruction. However, their
clinical proﬁle is characterized by relevant comorbid disease
and is clearly diﬀerent from the proﬁle of age-matched
subjects with “normal” lung function.
4.1. The Discrepancy between the Diﬀerent Deﬁnitions. The
discrepancyintheprevalenceofairwaysobstructiondepend-
ing on the criteria used to deﬁne disease is consistent with
other studies.
A similar diﬀerence in the prevalence of COPD depend-
ing on the deﬁnition used was reported for adults aged
40 years and over in New Zealand, showing a GOLD-
deﬁned prevalence of COPD of 14.2% and a LLN-deﬁned
prevalence of 9.0% [8]. A recent study based on spirometry
tests from a regional primary care diagnostic centre in the
Netherlands has shown that the discrepancy between the
two deﬁnitions for airﬂow obstruction increases along with
age, and that utilization of the ﬁxed FEV1/FVC cutoﬀ may
cause substantial COPD overdiagnosis in primary care [9].
In an elderly Chinese population (subjects aged 60 years and
above), the prevalence of airways obstruction using the ﬁxed4 Pulmonary Medicine
Table 3: Severity of airways obstruction in concordant and discordant obstructive cases.
Severity of airways obstruction Concordant obstructive cases§
(n = 192)
Discordant obstructive
cases#(n = 112) P-value
Possible normal variant (FEV1 >100% predicted) 22 (11.4%) 31 (27.7%) <.001
Mild obstruction (FEV1 70%–100% predicted) 115 (59.9%) 69 (61.6%) <.001
Moderate obstruction (FEV1 50%–70% predicted) 41 (21.4%) 12 (10.7%) .003
Severe obstruction (FEV1 < 50% predicted) 14 (7.3%) 0 (0.0%) /
§Concordant obstructive cases: FEV1/FVC<0.70 & <LLN.
#Discordant obstructive cases: FEV1/FVC<0.70 & ≥LLN.
Table 4: Characteristics of subjects with discordant obstructive ﬁndings and comparison to subjects with normal lung function, subjects
with restrictive lung function and subjects with concordant obstructive ﬁndings. Presented obstructive cases are limited to those with mild
to moderate impairment of FEV1 (FEV1 50%–100% pred.).
Discordant
obstructive
cases# (n = 81)
“Normal” lung
function$
(n = 414)
Restrictive lung
functionΨ
(n = 82)
Concordant
obstructive
cases§ (n = 156)
P-value∗ P-value∗∗ P-value∗∗∗
Characteristics
Age, mean (SE) 67 (0.99) 54.8 (0.50) 59.4 (1.16) 60.5 (0.95) <.001 <.001 <.001
Sex, male 66 (81.5%) 230 (55.6%) 48 (58.5%) 76 (48.7%) <.001 .002 <.001
Never smoker 33 (40.7%) 203 (49.0%) 35 (42.7%) 45 (28.9%) .172 .802 .065
Respiratory
Symptomsφ
Cough 14 (17.3%) 60 (14.5%) 19 (23.2%) 51 (32.7%) .796 .291 .009
Phlegm 20 (24.7%) 88 (21.3%) 23 (28.1%) 65 (41.7%) .893 .442 .004
Dyspnea 24 (29.6%) 62 (15.0%) 29 (35.4%) 41 (26.3%) .085 .084 .987
Comorbiditiesφ
Asthma 7 (8.6%) 29 (7.0%) 5 (6.1%) 21 (13.5%) .116 .172 .585
Heart disease 22 (27.2%) 30 (7.3%) 19 (23.2%) 23 (14.7%) .015 .179 .450
Hypertension 33 (40.7%) 135 (32.6%) 29 (35.4%) 55 (35.3%) .223 .970 .689
Diabetes 10 (12.4%) 32 (7.7%) 8 (9.8%) 10 (6.4%) .661 .538 .343
Stroke 6 (7.4%) 6 (1.5%) 4 (4.9%) 3 (1.9%) .228 .643 .156
Tuberculosis 2 (2.5%) 10 (2.4%) 2 (2.4%) 8 (5.1%) .479 .929 .195
#Discordant obstructive cases: FEV1/FVC<0.70 & ≥LLN.
§Concordant obstructive cases: FEV1/FVC<0.70 & <LLN.
$Normal lung function: FEV1/FVC>0.70 & FVC ≥ 80% pred.
ΨRestrictive lung function: FEV1FVC > 0.70 & FVC < 80% pred.
φResults adjusted for age.
∗P-value for diﬀerence between “discordant obstructive cases” and “normal lung function”.
∗∗P-value for diﬀerence between “discordant obstructive cases”and “restrictive lung function”.
∗∗∗P-value for diﬀerences between “discordant obstructive cases”and “concordant obstructive cases”.
ratio of 0.70 or using the LLN for the postbronchodilator
FEV1/FVC ratio was 25.9% and 12.4%, respectively [10].
A population-based study in Norway using pre-
bronchodilator spirometry data has shown that a FEV1/FVC
ratio below 0.70 was 50% more frequent in women aged 70
years and above compared to women aged 60–69 years. The
correspondingincreaseinmenwas80%.Onthebasisoftheir
results, the authors suggested the use of a threshold of 65%
(FEV1/FVC < 0.65) for subjects over the age of 70 years [11].
However, the discrepancy depending on the deﬁnition
used shows that either the GOLD criteria lead to a relevant
percentage of false positives or utilization of the lower limit
of normal to a relevant percentage of false negatives.
In general, any diagnostic test should have both high
sensitivity and high speciﬁcity. Since the FEV1/FVC ratio
declines with age, the ﬁxed ratio of 0.70 which is recom-
mended by the GOLD Initiative, may lead to considerable
overdiagnosis among healthy elderly people and underdiag-
nosis among young adults with early disease [3, 12–15]. The
problem of misclassiﬁcation might be pronounced in the
primary care setting, where early stages of disease are seen.
Therefore, utilization of the lower limit of normal insteadPulmonary Medicine 5
of a ﬁxed ratio has been especially recommended for COPD
screening in primary care [16].
4.2. Pros and Cons of the Diﬀerent Deﬁnitions. While utiliza-
tion of the ﬁxed ratio (0.70) is simple, convenient, and inde-
pendent from the existence of adequate reference equations
and specially adapted spirometers, the use of the age- and
sex-speciﬁc LLN as a threshold for the FEV1/FVC ratio may
lessentherisk ofoverdiagnosisofairways obstructionamong
the elderly and underdiagnosis among young adults.
Utilization of GOLD guidelines and unreﬂective inter-
pretation of test results may have negative consequences by
misclassifying healthy elderly subjects as COPD and thus
possibly causing unnecessary treatment and healthcare costs.
Withthisandothercriticalissuesinmind,agrowingnumber
of experts recommend to replace the 0.70 threshold with the
lower limit of normal threshold [17].
4.3. Discordant Obstructive Cases (In-Between Cases). When
one deﬁnition of airways obstruction (FEV1/FVC < LLN)
is thought to replace another deﬁnition (FEV1/FVC < 0.70)
the main point of interest is of course the number and
characteristicsofthosesubjectswhohavediscordant ﬁndings
(“normal” using the LLN but “abnormal” using the ﬁxed
ratio).
The comparisonofconcordantobstructive(FEV1/FVC<
0.70&<LLN)casesanddiscordantobstructive(FEV1/FVC<
0.70 & ≥LLN) cases revealed that subjects in the latter
group were signiﬁcantly older and signiﬁcantly more likely
to be male. In addition to this, discordant obstructive cases
reported less active smoking and less respiratory symptoms.
Our data suggest that utilization of the LNN as a threshold
for the FEV1/FVC ratio helps to identify clinically signiﬁcant
disease.
However, the clinical proﬁle of cases in between the two
deﬁnitions (discordant obstructive cases FEV1/FVC < 0.70
& ≥LLN) was characterized by high amounts of comorbid
disease. When adjustments for age were made, subjects with
discordant obstructive ﬁndings reported signiﬁcantly more
often a diagnosis of heart disease than subjects with normal
lungfunction. The clinicalproﬁleofsubjectswith discordant
obstructiveﬁndings was verysimilar totheproﬁleofsubjects
with restrictive lung function. Therefore, this data suggest
that a proportion of individuals with discordant obstructive
ﬁndingsmayhaveclinicallyimportantcomorbidities.Results
of a cohort study of the Cardiovascular Health Study have
shown that subjects classiﬁed as “normal” using the LLN
but abnormal using the GOLD criteria (0.70) were more
likely to die and to have a COPD-related hospitalization
during followup. The authors suggested that a ﬁxed ratio of
less than 0.70 identiﬁes at-risk patients, even among older
adults [18]. In an editorial on the deﬁnition of COPD the
author suggested that a ﬁnding that predicts a bad event or
premature death may probably represent “disease” [19].
4.4. Deﬁnition of Airways Obstruction and Underdiagnosis.
Besides the valuable discussion on what might be the
most precise deﬁnition of airways obstruction, one has
to take into consideration that currently the majority of
disease is still undiagnosed and untreated. The prevalence
of physician-diagnosed chronic airways obstruction in our
study population was 5.6%. This is far below both the
prevalence deﬁned by postbronchodilator FEV1/FVC < 0.70
(24.2%) and FEV1/FVC < LLN (15.3%). A recent study in
a primary care setting in Poland has shown that only 18.6%
of subjects with COPD had previously been diagnosed [20].
Overall, about 8%–13% of people in general population
surveys have airways obstruction without having a diagnosis
of obstructive lung disease [21].
4.5. Limitations. Limitations of our study include the use
of reference equations from the United States that may
not ideally apply to our population. However, using either
the NHANES III predictions or predictions based on the
study sample gave the same high COPD prevalence [5].
Another potential limitation of our study is that 200mcg of
salbutamol was administered instead of 400mcg, as recom-
mended by the GOLD guidelines. The prevalence of post-
BD airway obstruction would have been slightly lower with
a higher dose of BD. However, many pulmonary function
laboratories have been using 200mcg and we worried about
the risk of arrhythmias in our ﬁeld settings. The timing of
the postbronchodilator spirometry only 15 minutes after the
administration of salbutamol, while standard practice, may
nonetheless underestimate the true bronchodilator response
which may not be evident for 30–60 minutes.
5.Conclusion
The lower limit of normal (LLN) seems to be the more
reasonable threshold to deﬁne clinically signiﬁcant airways
obstruction. The risk of substantial overdiagnosis of COPD
and subsequent unnecessary treatment and healthcare costs
(due to utilization of a simple ﬁxed threshold) is pitted
against the reasonable desire for simplicity.
The results of this study indicate that subjects who
are in between the two deﬁnitions of airways obstruction
(discordant obstructivecases, FEV1/FVC<0.70& ≥LLN) do
not have clinically signiﬁcant airways obstruction. However,
t h e i rc l i n i c a lp r o ﬁ l ei sc h a r a cterized by relevant comorbid
disease and, therefore, they might be at risk and should be
followed carefully.
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